

60-Min Amyloid PET Standardized to a 90-Min Centiloid Reference on SiPM PET/CT

Koji Sohara¹, Hiroshi Matsuda², Sunao Mizumura^{1, 3}, Yujiro Nakaoka¹, Shogo Imai^{1, 2}, Masaya Suda¹, Hiroyuki Tajima¹, Hiromitsu Hayashi¹, Shinichiro Kumita¹

¹ Department of Radiology, Nippon Medical School Hospital, Tokyo, Japan

² Clinical Imaging Center for Healthcare, Nippon Medical School, Tokyo, Japan

³ Department of Radiology, Toho University Omori Medical Center, Tokyo, Japan

2026 JSRS Meeting
Copenhagen, Denmark

2026 JSRS Meeting | Copenhagen, Denmark

Disclosure of Conflict of Interest

Name of first author: Koji Sohara

- **Institutional COI: This study was conducted with institutional research support from Nihon Medi-Physics Co., Ltd.**
- PI: Koji Sohara
- Acceptance of researchers: None
- Personal COI (first author): None

Background (1): Clinical need for a shorter amyloid PET protocol

- ^{18}F -flutemetamol amyloid PET supports diagnosis, differential diagnosis, and selection for anti-A β therapy.
- The conventional delayed static protocol is acquired at approximately 90 min post-injection.
- Reducing the waiting interval may decrease patient burden and improve scanner workflow, especially in elderly or cognitively impaired patients.
- Any shortened protocol must preserve the clinical visual read, because visual assessment remains the primary basis of routine interpretation.

Background (2): Why VA and CL validation are both required

- **Visual assessment:** captures the clinically decisive global amyloid status but can be vulnerable in borderline regional uptake.
- **Centiloid quantification:** complements VA near thresholds and enables harmonized reporting across scanners, sites, and processing pipelines.
- **SiPM PET/CT:** offers high sensitivity and image quality, making a shorter delayed acquisition plausible.
- **Methodological gap:** a 60-min acquisition must be validated against the 90-min reference for both VA concordance (Analysis 1) and CL bridging (Analysis 2).

Study Objective

To determine whether 60-min delayed ^{18}F -flutemetamol PET on digital SiPM PET/CT is interchangeable with conventional 90-min imaging by evaluating:

- **Analysis 1:** visual assessment agreement across readers and between 60- and 90-min images.
- **Analysis 2:** quantitative agreement between converted $\text{CL}_{90}(\text{est.60})$ and measured CL_{90} on the conventional 90-min Centiloid scale.

Study population and design

Single-center retrospective observational study.

Participants: **63 consecutive** patients who underwent **^{18}F -flutemetamol amyloid PET** at the Nippon Medical School Clinical Imaging Center for Healthcare between February and September 2025, using a **semiconductor (SiPM) PET system**.

For the present analysis, we included cases in which both 60-min and 90-min post-injection images were available.

The study protocol was approved by the institutional review board (approval No. M-2025-428), and informed consent was obtained using an opt-out procedure.

Pre-treatment brain imaging to exclude:

Major cerebrovascular lesions Intracranial hematoma CSF distribution imbalance (e.g., hydrocephalus) Brain tumors

Encephalopathy / encephalitis Other findings contraindicating anti-A β antibody therapy

Modalities: screening MRI or same-day low-dose CT

Participant characteristics

Characteristic	Overall (n = 63)
Participants, n	63
Age, years, mean $\pm$ SD	77.7 $\pm$ 7.8
Female, n (%)	44 (69.8%)
Education, years, mean $\pm$ SD	13.2 $\pm$ 2.4 (n = 53)
MMSE, mean $\pm$ SD	24.9 $\pm$ 2.6 (n = 57)
Global CDR, median [IQR]	0.5 [0.5, 0.5] (n = 57)
Exam type, n (Insurance/Checkup)	57/6

Imaging conditions

Radiotracer	^{18}F -flutemetamol
Injected dose	Mean 223.3 ± 23.8 MBq (range 172.4–268.0 MBq)
Uptake time (60-min images)	59.9 ± 1.7 min (range 55–67 min)
Uptake time (90-min images)	89.9 ± 1.1 min (range 88–96 min)
Acquisition time	20 min per static scan
PET scanners	Siemens Biograph Vision 450 (38 cases) Canon Cartesion Prime PCD-1000 (25 cases)

Imaging conditions

Biograph Vision 450 (BV, Siemens) / Cartesion Prime PCD-1000A (CP, Canon)

CT-AC (for attenuation correction)

kVp: 120 / 120 mA (AEC / fixed): AEC / 300

Slice thickness (mm): 2 / 2 Pitch: 0.55 / 0.813

Reconstruction kernel: Hf38 / FC07 MAR: OFF / OFF

PET Reconstruction

Method: 3D OSEM / 3D OSEM Iterations / subsets: 4×5 / 5×12

TOF: ON (214 ps / 238 ps) Gaussian post filter (FWHM): 2.5 mm / 4.0 mm

Matrix / Voxel

Matrix: 440×440 / 128×128 Pixel size (mm): 0.825 / 2.11

QC & EARL

Normalization updated by QC with Ge calibration source (both)

Cross-calibration: 2023/3/20 (SIEMENS), 2025/8/4 (CANON)

Latest QC: Pass / Pass EARL 18F/11C brain PET/CT: No / No

Key terminology

VA₆₀ / VA₉₀: Visual assessment on the 60-min and 90-min images, respectively

SUV_{R60} / SUV_{R90}: Standardized uptake value ratios referenced to the whole cerebellum

CL₉₀: Centiloid derived from the 90-min image

CL₉₀(est.60): 90-min-equivalent Centiloid estimated from the 60-min image using the study-derived calibration

CL₉₀(pub.60): 90-min-equivalent Centiloid estimated from the 60-min image using the published conversion formula

Takemoto ANM. 2025

Quantification (SUVR and CL) and Statistical analysis

SUVR₆₀ and SUVR₉₀ denote whole-cerebellum–referenced SUVR [SUVR(WC)] measured from the 60- and 90-min images, respectively.

CL₉₀ was derived from SUVR₉₀ using the vendor-implemented SUVR-to-CL transformation (VIZcalc in medi+FALCON).

Analyses were performed using SPSS (version 29.0.2) and Python (version 3.11.2).

Analysis overview and statistical methods

Analysis 1: Robustness of the visual reference standard across readers and time points

- Inter-reader agreement was assessed using Fleiss' κ (three experienced readers)
- Between-time-point agreement was assessed using Cohen's κ and McNemar's exact test

Analysis 2: Quantitative agreement between $CL_{90}(\text{est.60})$ and CL_{90}

- Linear regression was used to estimate 90-min CL from 60-min SUVR, overall and by platform.
- Agreement between estimated and observed 90-min CL was evaluated using Pearson correlation and Bland–Altman analysis.


RESULTS:Participant characteristics (majority VA at 60 min)

Characteristic	Overall	Aβ−	Aβ+	p
Participants, n	63	30	33	
Age, years, mean ± SD	77.7 ± 7.8	77.0 ± 9.2	78.2 ± 6.3	0.549
Female, n (%)	44 (69.8%)	21 (70.0%)	23 (69.7%)	1.000
Education, years, mean ± SD (available n)	13.2 ± 2.4 (n = 53)	12.7 ± 2.5 (n = 24)	13.6 ± 2.4 (n = 29)	0.175
MMSE, mean ± SD (available n)	24.9 ± 2.6 (n = 57)	24.8 ± 2.6 (n = 24)	25.1 ± 2.6 (n = 33)	0.702
Global CDR, median [IQR] (available n)	0.5 [0.5, 0.5] (n = 57)	0.5 [0.5, 0.5] (n = 24)	0.5 [0.5, 0.5] (n = 33)	0.870
Scanner (BV/CP), n	BV: 38; CP: 25	BV: 16; CP: 14	BV: 22; CP: 11	0.313
Exam type (insurance/checkup), n	57/6	24/6	33/0	

Analysis 1: Visual Assessment (Readers and Gold Standard)

- Three nuclear medicine physicians (A: 47 years, B: 37 years, C: 12 years of reading experience).
- All are board-certified radiologists and nuclear medicine specialists focusing on brain imaging.
- Dedicated Vizamyl Viewer was used under blinded conditions (randomized anonymized IDs).
- Global amyloid status (positive / negative) was evaluated independently for 60-min and 90-min images.
- Final global visual judgment was defined as positive or negative when at least two of the three readers agreed.

Visual Read Criteria and Representative Cases (60 vs 90 min)



Negative: Cortical gray matter uptake lower than white matter with preserved gray–white contrast; uptake limited to white matter/choroid plexus/meninges is not positive.

Positive: Loss of gray–white matter contrast due to increased cortical uptake in ≥ 1 key 5 key regions (frontal, parietal, lateral temporal, or posterior cingulate/precuneus).

Analysis 1: Visual Agreement and Gold Standard

- Inter-reader agreement was evaluated for both 60-min and 90-min images.
- Complete agreement among all three readers was recorded, as well as pairwise agreement (A–B, A–C, B–C).
- Agreement was quantified using Cohen's κ (pairwise) and Fleiss' κ (overall).
- Consensus (gold standard) was defined by majority rule (≥ 2 of 3 readers positive or negative).
- The numbers of visually positive and negative cases were used as the reference for subsequent ROC analyses.

Result1-1 Per-Reader Visual Calls (60 vs 90 min)

60-min

Reader	Positive (n)	Positive (%)	Negative (n)	Negative (%)
A	35	55.6	28	44.4
B	34	54.0	29	46.0
C	32	50.8	31	49.2
Consensus	30	47.6	33	52.4

90-min

Reader	Positive (n)	Positive (%)	Negative (n)	Negative (%)
A	34	54.0	29	46.0
B	31	49.2	32	50.8
C	28	44.4	35	55.6
Consensus	31	49.2	32	50.8

Result1-2 Inter-reader Agreement (60-min images)

Pair / All readers	Agreements (n / 63)	Agreement (%)	κ
A vs B	60 / 63	95.2	0.904
A vs C	60 / 63	95.2	0.905
B vs C	61 / 63	96.8	0.936
A, B, C all	59 / 63	93.7	0.915

*κ was calculated using Cohen's kappa for pairwise agreement and Fleiss' kappa for three-reader agreement.

Result1-3 Inter-reader Agreement (90-min images)

Pair / All readers	Agreements (n / 63)	Agreement (%)	κ
A vs B	60 / 63	95.2	0.905
A vs C	57 / 63	90.5	0.811
B vs C	58 / 63	92.1	0.841
A, B, C all	56 / 63	88.9	0.852

*κ was calculated using Cohen's kappa for pairwise agreement and Fleiss' kappa for three-reader agreement.

Result1-4

Agreement of Consensus Reads Between 60-min and 90-min images

Consensus	Positive (n)	Positive (%)	Negative (n)	Negative (%)
60-min	30	47.6	33	52.4
90-min	31	49.2	32	50.8

*Consensus (gold standard) was defined by majority rule (≥ 2 of 3 readers positive or negative).

Concordant consensus

between 60-min and 90-min scans: 62 / 63 (98.4%)


Cohen's κ between 60-min and 90-min consensus reads: 0.97

Discordant cases: 1 / 63 (1.6%)


Therefore, majority visual assessment was used as the reference standard for subsequent analyses.

Result 1-5: Discordant Case Between 60-min and 90-min Reads

60-min



90-min




Result 1-5: Discordant Case Between 60-min and 90-min Reads

60-min

2 out of 3 readers
positive

→ **positive**


Right temporal
lateral temporal



90-min

All readers
negative

→ **negative**



Analysis 2: Agreement Between CL60_SiPM and CL90_SiPM

Aim: To evaluate the agreement between CL60_SiPM and CL90_SiPM.

Imaging indices:

SUV_R60 / SUV_R90: Standardized uptake value ratios from 60- and 90-min images.

CL90_SiPM (reference CL): Centiloid from the 90-min SiPM image.

CL60_SiPM (standardized CL): Centiloid from the 60-min SiPM image, standardized from SUV_R60 using an institutional regression model.

Correlation analyses:



Pearson correlations for CL60 vs SUV_R60 and CL90 vs SUV_R90.

Agreement analyses:

Scatter plot (x: CL60_SiPM, y: CL90_SiPM) with the identity line ($y = x$).

Bland–Altman plot using mean CL (x-axis) vs difference (CL60_SiPM – CL90_SiPM) (y-axis); report bias and 95% limits of agreement.

Analysis 2_1: Quantitative agreement between Centiloid values derived from 60- and 90-min images.



Analysis 2_2: Quantitative agreement between $CL_{90}(\text{est.60})$ and CL_{90} (overall and scanner-stratified)

Overall (SiPM, n = 63)

$$CL_{90}(\text{est.60}) = 146.66 \times SUVR_{60} - 152.73$$
$$CL_{90} = 1.00 \times CL_{90}(\text{est.60}) + 0.01 \quad (r = 0.998)$$

BV (n = 38)

$$CL_{90}(\text{est.60}) \text{ (BV)} = 146.61 \times SUVR_{60} - 152.39$$
$$CL_{90} = 1.00 \times CL_{90}(\text{est.60}) + 0.29 \quad (r = 0.998)$$

CP (n = 25)

$$CL_{90}(\text{est.60}) \text{ (CP)} = 146.98 \times SUVR_{60} - 153.55$$
$$CL_{90} = 1.00 \times CL_{90}(\text{est.60}) - 0.49 \quad (r = 0.997)$$

Analysis 2_3: Quantitative agreement between $CL_{90}(\text{pub.60})$ and CL_{90}

Overall (SiPM, n = 63)

$$CL_{90}(\text{pub.60}) = 143.330 \times SUVR_{60} - 150.151$$
$$CL_{90} = 1.02 \times CL_{90}(\text{pub.60}) + 0.91 \quad (r = 0.997)$$

Discussion: Integrated interpretation of Analysis 1 and 2

- **Core finding:** 60-min SiPM 18F-flutemetamol PET preserved both clinically anchored VA and quantitative CL agreement with the 90-min reference.
- **Analysis 1 - VA:** Majority reads were concordant in 62/63 cases (98.4%; $\kappa = 0.968$), with high inter-reader reliability at both time points.
- **Analysis 2 - CL:** After conversion, $CL_{90}(\text{est.60})$ closely matched measured CL_{90} (slope 1.003; $r = 0.997$; CCC = 0.997; bias -0.01 CL; LoA $\approx \pm 6$ CL).
- **Clinical use:** A 60-min protocol can reduce waiting time, but near-threshold cases should integrate VA, converted CL, and clinical context; conversion remains pipeline- and site-specific.

Limitations

This was a single-center within-subject study using two SiPM systems; generalizability to other scanners, reconstructions, and sites remains to be established.

The study assessed comparative concordance, not diagnostic accuracy against an independent biological or neuropathological reference standard.

The conversion formulas were pipeline-specific, and interpretation near the positivity boundary may shift with acquisition timing and processing details.

Conclusions

- **Visual agreement:** 60- and 90-min majority VA showed almost perfect concordance (62/63, 98.4%; $\kappa = 0.968$).
- **Quantitative agreement:** Converted 60-min CL values were essentially interchangeable with measured CL₉₀ (CCC = 0.997; bias -0.01 CL).
- **Practical conclusion:** With protocol-specific CL conversion, 60-min delayed SiPM amyloid PET can serve as a practical alternative to the conventional 90-min protocol.
- **Caution:** Borderline cases near positivity thresholds should be interpreted using both VA and converted CL, together with clinical context.

Mange tak for jeres opmærksomhed.